Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02315781
Other study ID # H14-00867
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date December 6, 2017

Study information

Verified date May 2018
Source Pacific Parkinson's Research Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Parkinson's disease (PD) is a progressive neurological disease that has effects on both movement and mental health. One of the most common mental health complications of PD is depression. Up to 30% of Parkinson's patients will experience depression at some point. We aim to investigate whether transcranial direct current stimulation (tDCS), a type of electrical stimulation for the brain, can improve depression in PD as well as improve motor function in PD.


Description:

The purpose of this double-blind, randomized control design study is to investigate the efficacy of 15-sessions of tDCS (versus 15-sessions of sham tDCS) to treat depression in PD. We will also assess dopamine function in a smaller cohort of participants before and after their 15 sessions of tDCS by using PET scanning.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date December 6, 2017
Est. primary completion date December 6, 2017
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

1. are outpatients,

2. are voluntary and competent to consent to treatment,

3. have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of major depressive disorder (MDD),

4. have a diagnosis of PD according to the UK PD brain bank criteria,

5. are 19 years of age or more,

6. have a score > 13 on the Beck Depression Inventory-II (BDI-II),

7. still have depressive symptoms after 6 weeks or more of antidepressant (SSRI) medication treatment (and on a stabilized dose of at least 4 weeks),

8. are able to adhere to the treatment schedule,

9. are proficient in written and verbal English.

Exclusion Criteria:

1. have a history of substance dependence or abuse within the last 6 months,

2. have a concomitant significant unstable medical illness,

3. have active suicidal intent,

4. have any history of seizure or medication-resistant epilepsy in the family,

5. have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms

6. have a MINI diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD,

7. have failed a course of ECT in the current episode or previous episode,

8. have received tDCS or other neurostimulation therapy for any previous indication due to the potential compromise of expectancy effects,

9. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes, or developmental disorder,

10. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed,

11. are taking a non-SSRI antidepressant medication,

12. are pregnant (women of childbearing age only).

Exclusion Criteria for PET:

1. unable to tolerate staying off anti-parkinsonian medication for 12-18 hours pre-PET scan,

2. have a history of radiation therapy treatment or other high amounts of radiation.

Exclusion Criteria for MRI:

- Artificial heart valve;

- Brain aneurysm clip;

- Electrical stimulator for nerves or bones;

- Ear or eye implant;

- Implanted drug infusion pump;

- Coil, catheter, or filter in any blood vessel;

- Orthopedic hardware (artificial joint, plate, screws);

- Other metallic prostheses;

- Shrapnel, bullets, or other metal fragments;

- Surgery or tattoos (including tattooed eyeliner) in the last six weeks.

Study Design


Intervention

Device:
active tDCS
transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
Sham tDCS
Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.

Locations

Country Name City State
Canada Pacific Parkinson's Research Centre Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Pacific Parkinson's Research Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary HAMD score an assessment of the severity of depression 12 weeks
Secondary Dopamine levels PET scanning will be used to assess dopamine levels before and after sham/active tDCS in 20 participants 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A